Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Infectious Disease
•
Vaccines
•
Travel and Tropical Medicine
How do you approach vaccination, particularly the use of live vaccines such as yellow fever, in a patient with rheumatoid arthritis receiving a TNF inhibitor who is planning travel to Africa?
Related Questions
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
In light of recent measles outbreaks, have you adjusted your vaccination counseling or preventive strategies for adult immunocompromised patients?
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
What is the recommended fungal workup in an immunocompromised patient after 5 days of persistent fever?
In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
What are your practice recommendations regarding live vaccinations in infants/children of women who are currently on DMARDs and are breastfeeding?
When trying to increase infliximab for active disease (inflammatory arthritis or sarcoidosis), do you prefer to increase dosage or reduce frequency between doses?
Is it better to give dose 2 of the mRNA 2024-2025 Covid-19 vaccine at month 2 or month 6 after dose 1 in moderately immunocompromised patients?
